Dermapharm successfully acquires Allergopharma
Grünwald, March 31, 2020 – Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas, successfully completes its acquisition of Allergopharma.
This Tuesday, March 31, 2020, saw the closing of the acquisition of Allergopharma GmbH & Co. KG, based in Reinbek near Hamburg, by Dermapharm Beteiligungs GmbH. The purchase contract already concluded on February 19, 2020, was subject to the approval of the relevant supervisory authorities. The transfer of Allergopharma’s business in China is expected in the second half of 2020.
Allergopharma specializes in the subcutaneous hyposensitization of allergies and offers a wide range of high-dose hypoallergenic preparations, so-called allergoids, as well as a large selection of allergens for diagnostics.
“With Allergopharma, we are expanding our expertise in immunotherapy for the treatment of allergies and further developing our therapeutic area of dermatology,” commented Dr Hans-Georg Feldmeier, Chairman of the Management Board of Dermapharm Holding SE.
The contracting parties have agreed not to disclose the purchase price.
Dermapharm – Pharmaceutical Excellence “Made in Germany”
Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Grünwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company’s integrated business model comprises in-house development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a medical and pharmaceutical sales force. Dermapharm has more than 250 active pharmaceutical ingredients for more than 900 marketing authorisations (Arzneimittelzulassungen), which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. This assortment makes the company unique. In addition to Germany, the company’s core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm’s business model also includes a parallel import business, which operates under the “axicorp” brand. Based on revenues, Dermapharm was among the top five parallel import companies in Germany in 2019. In the “Herbal Extracts” segment, Dermapharm has access to the growth market for herbal pharmaceuticals through the Spanish company Euromed S.A., one of the leading manufacturers of herbal extracts and natural active ingredients.
With a consistent R&D strategy and numerous successful product and company acquisitions over the past 25 years, Dermapharm has continuously optimised its business and provided external growth impulses in addition to organic growth. Dermapharm intends to continue on this profitable growth course in the future. The company is focusing on a three-pillar strategy: in-house development of new products, increase of its international footprint and further acquisitions.
Investor Relations & Corporate Communications
Phone: +49 (0)89 – 64186-233
Fax: +49 (0)89 – 64186-165
Phone: +49 (0)611 – 205855-28
Fax: +49 (0)611 – 205855-66